This is an old revision of this page, as edited by Boghog(talk | contribs) at 04:50, 25 September 2019(templated cites). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 04:50, 25 September 2019 by Boghog(talk | contribs)(templated cites)
NS-2664 (LS-193,048) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company NeuroSearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2664 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has potent anticonvulsant effects in animal studies, but a relatively short duration of action, and produces little sedative effects or physical dependence.[1]
References
^Mirza NR, Nielsen EØ (March 2006). "Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?". The Journal of Pharmacology and Experimental Therapeutics. 316 (3): 1378–85. doi:10.1124/jpet.105.094474. PMID16352707.
(what is this?) (verify)